Abstract
Background Fetal birth weight and placental weight have been extensively studied and used for clinical assessment of fetal development and maternal health. The ratio of fetal and placental weight as a tool for clinical use in human pregnancy is less studied. We compared the fetal birth weight, placental weight and fetal placental ratio in term pregnancy to see if fetal and placental ratio is useful in assessment of maternal health and pregnancy complication as well as fetal growth and development in singleton pregnancy.
Material and methods We have collected the fetal birth data, maternal pregnancy data and placental pathology data from March 2000 to November 2021 in a single urban hospital. We compared the fetal birth weight, placental weight and fetal placental ratio in assessment of fetal growth, maternal pregnancy complications, and placental pathology with special emphasis on the role of fetal placental ratio.
Results A total 3302 pairs of neonates and placentas from term singleton pregnancy were reviewed and fetal birth weight and placental weight were moderately correlated with Pearman’s correlation coefficiency R=0.66. Fetal placental ratio as a proxy of placental efficiency was significantly associated with various pregnancy complications and placental pathology, and these associations were different from those of fetal birth weight or placental weight alone. High placental efficiency (90 percentile or greater) was associated with ethnic White, SARS-CoV2 status, category 2 fetal heart tracing and maternal inflammatory response in placenta while low placental efficiency (less than 10 percentile) was associated with ethnic Black, Asian and Hispanic, preeclampsia/pregnancy induced hypertension and gestational diabetes mellitus.
Conclusion Fetal placental ratio was shown to be a useful indicator different from fetal birth weight and placental weight alone. Maternal and environmental factors were shown to have differential effects on fetal and placental growth. Understanding the mechanism of differential fetal and placental growth will help better manage the clinical relevant conditions such as IUGR and macrosomia.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study did not receive any funding.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This work was approved by the Institutional Review Board of New York Presbyterian Brooklyn Methodist Hospital [1592673-1] (approval date 4-13-2020).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data produced in the present work are contained in the manuscript.
